 |
Finsbury is handling Takeda Pharmaceuticals' fifth bid for rare drug specialist Shire PLC of Dublin.
If successful, the sweetened $60B cash/stock offer would mark the largest-ever Japanese acquisition of a western firm and propel Takeda into the top-ranks of global drug companies.
Takeda notes the improved bid represents a 58 percent premium over the closing price of Shire shares on March 23, the day before rumors surfaced about a takeover bid.
It said that completion of the deal would give Shire shareholders "a very meaningful stake in a leading global biopharmaceutical company" and benefits from the synergies flowing from the deal.
Shire is considering Takeda's latest bid.
Finsbury's London team of James Murgatroyd Rollo Head and Anjali Unnikrishnan are working the Takeda bid with Kal Goldberg and Chris Ryall in New York.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
April is National Minority Health Month, spotlighting the urgency to improve health outcomes in communities of color.
In a recent conversation about the evolving media landscape, Doug Simon, CEO of D S Simon Media, spoke with Campbell O’Connor, Group Director, Media & Engagement at Real Chemistry, about how AI is influencing media relations and healthcare communications.
